Franklin Templeton has launched the Templeton Emerging Markets Debt ETF (TEMD), aiming to give investors targeted exposure to both hard and local currency debt from developing economies, capitalizing on the asset class's recent strong performance.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
London's blue-chip index surged to a historic high as investors rotated into defensive sectors, shrugging off a brutal sell-off in precious metals and oil triggered by geopolitical shifts and regulatory moves.
Sugar futures extended their sharp decline this week, with London white sugar hitting a five-year low, as robust harvests from Brazil and India signal a prolonged period of ample global supplies.
A new study reveals the cost gap between Waymo's driverless vehicles and human-driven Uber and Lyft rides is shrinking, signaling a pivotal moment for the competitive robotaxi industry.
A new Deloitte report urges enterprises to embed accountability and oversight from the start, arguing that governance is not a barrier but an accelerator for scaling autonomous AI systems.
Former Congressman Colin Allred delivers a pointed public rebuke of Texas House member James Talarico, alleging derogatory comments were made during the heated Democratic Senate primary campaign.
After a sharp January sell-off, Shopify's stock is hovering near a significant long-term trendline—a level that has preceded notable rallies in the past.
CNBC's Jim Cramer reaffirmed his bullish stance on Rio Tinto, highlighting the mining giant's role as a strategic hedge against geopolitical and economic volatility during the show's Lightning Round.
CNBC's Jim Cramer reaffirmed his bullish stance on Palantir Technologies during a recent 'Mad Money' segment, placing the data analytics firm in the same league as established giants like ServiceNow and Salesforce.
CNBC's Jim Cramer concedes he misjudged the explosive demand for Apple's iPhone 17, which powered the tech giant to a staggering earnings beat that caught Wall Street off guard.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Swiss banking giant UBS is preparing to offer a limited group of its wealth management clients access to trade Bitcoin and Ether, marking a significant but measured step into digital assets as it responds to client demand and a shifting regulatory landscape.
In a strategic pivot, Bed Bath & Beyond acquires Tokens.com, aiming to launch a platform for tokenizing real-world assets like real estate and securities, with shares rising on the news.
Despite both tech giants aggressively investing in AI, their stock prices are telling divergent stories. We examine the underlying fundamentals that make them resilient picks for any portfolio, regardless of short-term volatility.
While Nufarm's share price has seen a modest 10% recovery in recent months, investors who bought three years ago are still sitting on heavy losses, with the stock down 60% over that period. The agricultural chemical company's declining revenue and lack of profitability continue to weigh on market sentiment.
A detailed look at the SPDR Gold Shares (GLD) and iShares Silver Trust (SLV) reveals a tale of two metals: one prized for stability, the other for its volatile potential. For investors navigating uncertain markets, the choice between them hinges on more than just recent returns.
